A protective effect of sulindac against chemically-induced primary colonic tumours in mice

J Pathol. 1988 Dec;156(4):341-7. doi: 10.1002/path.1711560411.


Sulindac, a non-steroidal anti-inflammatory drug, has been reported to lead to tumour regression in cases of human polyposis coli. We have investigated the effects of this drug on the growth of 1,2-dimethylhydrazine (DMH)-induced mouse colonic tumours. In one experiment, DMH and oral sulindac were administered concurrently to a group of mice for a period of up to 24 weeks, while a control group of animals received DMH only for the same period. Sulindac caused a significant reduction in both the number of mice with colonic tumours and the number of tumours per mouse. In a second experiment, two groups of mice which had already been treated with DMH for 17 weeks received either sulindac or not for 78 days. In this experiment sulindac had no effect. These results demonstrate that sulindac has a protective effect against the chemical induction of colonic tumours in mice, but does not cause the regression of established tumours.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1,2-Dimethylhydrazine
  • Adenocarcinoma / pathology
  • Adenoma / pathology
  • Animals
  • Carcinogens
  • Colonic Neoplasms / chemically induced
  • Colonic Neoplasms / pathology
  • Colonic Neoplasms / prevention & control*
  • Dimethylhydrazines
  • Female
  • Indenes / therapeutic use*
  • Mice
  • Mice, Inbred BALB C
  • Sulindac / administration & dosage
  • Sulindac / therapeutic use*


  • Carcinogens
  • Dimethylhydrazines
  • Indenes
  • Sulindac
  • 1,2-Dimethylhydrazine